AC
JAZZ icon

Armistice Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Armistice Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-651,626
Closed -$80.1M – 374
2023
Q4 		$80.1M Buy
651,626
+338,882
+108% +$42.3M 1.09% 11
2023
Q3 		$40.5M Sell
312,744
-143,256
-31% -$19.1M 0.62% 31
2023
Q2 		$56.5M Buy
+456,000
New +$61.4M 0.82% 25
2022
Q3 		– Sell
-278,000
Closed -$43.4K – 222
2022
Q2 		$43.4K Sell
278,000
-194,000
-41% -$29.9M 0.76% 34
2022
Q1 		$73.5M Sell
472,000
-406,000
-46% -$58.9M 1.42% 13
2021
Q4 		$112M Buy
878,000
+554,000
+171% +$72.8M 1.83% 8
2021
Q3 		$42.2M Buy
+324,000
New +$49M 0.71% 36

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital's JAZZ Position: Q1 2024 in Review

Armistice Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 651,626 shares — an estimated $80.1M sold.

Armistice Capital first reported a position in JAZZ in Q3 2021 and held it in 7 quarters. The position peaked at $112M in Q4 2021. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Armistice Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 651,626 Jazz Pharmaceuticals shares in Q1 2024, an estimated $80.1M.
  • Armistice Capital first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Armistice Capital's Jazz Pharmaceuticals position peaked at $112M in Q4 2021.
  • 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.